Business
COLLEGIUM PHARMACEUTICAL, INC: We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder ("ADHD") and moderate to severe pain.
Revenue increased 23.6% to $780.6M, while Net income decreased 9.1% to $62.9M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $780.6MOK
- Profitability — Net income $62.9MOK
- Cash generation — Free cash flow $327.6MOK
- Insiders — 0 buys; 12 sells in 365 daysNote
- Capital — share repurchases were $25.1MNote
Where the revenue comes from
Fiscal 2025, as COLLEGIUM PHARMACEUTICAL, INC reports it. History and quarterly detail are in the app.
- Belbuca$221.7M
- Xtampza ER$199.3M
- Jornay PM$148.9M
- Nucynta IR$115.3M
- Nucynta ER$81.0M
Leadership changes
From COLLEGIUM PHARMACEUTICAL, INC's own filings, the day they're filed.
- Scott Dreyer · Chief Commercial Officer · departureeff. 2026-08-30
- Thomas Smith · Chief Medical Officer · departureeff. 2026-05-11
- John Fallon · director · departureeff. 2026-04-02
Latest filings
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-05-15
- 8-K · Company announcement2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about COLLEGIUM PHARMACEUTICAL, INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.